Ensysce Biosciences Stock Performance
| ENSC Stock | USD 0.59 0.13 27.83% |
The firm shows a Beta (market volatility) of 1.45, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ensysce Biosciences will likely underperform. At this point, Ensysce Biosciences has a negative expected return of -2.15%. Please make sure to confirm Ensysce Biosciences' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Ensysce Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Ensysce Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1:15 | Last Split Date 2024-12-06 |
1 | Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. | 11/17/2025 |
2 | Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach | 11/20/2025 |
3 | Acquisition by Lynn Kirkpatrick of 6585 shares of Ensysce Biosciences at 2.59 subject to Rule 16b-3 | 11/24/2025 |
4 | Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR Overdose Protection Technology | 12/02/2025 |
5 | Acquisition by Benton Andrew of 65850 shares of Ensysce Biosciences at 3.35 subject to Rule 16b-3 | 12/08/2025 |
6 | Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid | 12/09/2025 |
7 | Ensysce Biosciences Shareholders Approve Key Corporate Actions - TipRanks | 01/07/2026 |
8 | Volume Recap Is Ensysce Biosciences Inc stock dividend yield sustainable - Trade Exit Report Low Risk High Win Rate Picks - moha.gov.vn | 01/13/2026 |
9 | Insider Trading | 01/26/2026 |
10 | Acquisition by Weil A Lorne of 730110 shares of Ensysce Biosciences at 11.5 subject to Rule 16b-3 | 02/04/2026 |
Ensysce Biosciences Relative Risk vs. Return Landscape
If you would invest 204.00 in Ensysce Biosciences on November 11, 2025 and sell it today you would lose (156.61) from holding Ensysce Biosciences or give up 76.77% of portfolio value over 90 days. Ensysce Biosciences is currently does not generate positive expected returns and assumes 5.8511% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Ensysce, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ensysce Biosciences Target Price Odds to finish over Current Price
The tendency of Ensysce Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.59 | 90 days | 0.59 | more than 93.0 |
Based on a normal probability distribution, the odds of Ensysce Biosciences to move above the current price in 90 days from now is more than 93.0 (This Ensysce Biosciences probability density function shows the probability of Ensysce Stock to fall within a particular range of prices over 90 days) .
Ensysce Biosciences Price Density |
| Price |
Predictive Modules for Ensysce Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ensysce Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ensysce Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ensysce Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ensysce Biosciences is not an exception. The market had few large corrections towards the Ensysce Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ensysce Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ensysce Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -2.27 | |
β | Beta against Dow Jones | 1.45 | |
σ | Overall volatility | 0.48 | |
Ir | Information ratio | -0.4 |
Ensysce Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ensysce Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ensysce Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Ensysce Biosciences generated a negative expected return over the last 90 days | |
| Ensysce Biosciences has high historical volatility and very poor performance | |
| Ensysce Biosciences has some characteristics of a very speculative penny stock | |
| Ensysce Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Ensysce Biosciences currently holds 301.66 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 5.21 M. Net Loss for the year was (7.99 M) with loss before overhead, payroll, taxes, and interest of (6.08 M). | |
| Ensysce Biosciences currently holds about 3.15 M in cash with (7.5 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Ensysce Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Weil A Lorne of 730110 shares of Ensysce Biosciences at 11.5 subject to Rule 16b-3 |
Ensysce Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ensysce Stock often depends not only on the future outlook of the current and potential Ensysce Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ensysce Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.7 M | |
| Cash And Short Term Investments | 3.5 M |
Ensysce Biosciences Fundamentals Growth
Ensysce Stock prices reflect investors' perceptions of the future prospects and financial health of Ensysce Biosciences, and Ensysce Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ensysce Stock performance.
| Return On Equity | -2.94 | ||||
| Return On Asset | -1.1 | ||||
| Profit Margin | (2.44) % | ||||
| Operating Margin | (7.59) % | ||||
| Current Valuation | 390.43 K | ||||
| Shares Outstanding | 3.63 M | ||||
| Price To Book | 1.39 X | ||||
| Price To Sales | 0.37 X | ||||
| Revenue | 5.21 M | ||||
| Gross Profit | (6.08 M) | ||||
| EBITDA | (6.73 M) | ||||
| Net Income | (7.99 M) | ||||
| Cash And Equivalents | 3.15 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 301.66 K | ||||
| Debt To Equity | 6.91 % | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (7.5 T) | ||||
| Earnings Per Share | (6.35) X | ||||
| Market Capitalization | 1.68 M | ||||
| Total Asset | 5.6 M | ||||
| Retained Earnings | (129.54 M) | ||||
| Working Capital | 3.14 M | ||||
About Ensysce Biosciences Performance
By analyzing Ensysce Biosciences' fundamental ratios, stakeholders can gain valuable insights into Ensysce Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ensysce Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ensysce Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -961 K | -1 M | |
| Return On Tangible Assets | (1.28) | (1.35) | |
| Return On Capital Employed | (1.79) | (1.70) | |
| Return On Assets | (1.28) | (1.35) | |
| Return On Equity | (1.94) | (1.84) |
Things to note about Ensysce Biosciences performance evaluation
Checking the ongoing alerts about Ensysce Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ensysce Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ensysce Biosciences generated a negative expected return over the last 90 days | |
| Ensysce Biosciences has high historical volatility and very poor performance | |
| Ensysce Biosciences has some characteristics of a very speculative penny stock | |
| Ensysce Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Ensysce Biosciences currently holds 301.66 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 5.21 M. Net Loss for the year was (7.99 M) with loss before overhead, payroll, taxes, and interest of (6.08 M). | |
| Ensysce Biosciences currently holds about 3.15 M in cash with (7.5 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Ensysce Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Weil A Lorne of 730110 shares of Ensysce Biosciences at 11.5 subject to Rule 16b-3 |
- Analyzing Ensysce Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ensysce Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Ensysce Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ensysce Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ensysce Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ensysce Biosciences' stock. These opinions can provide insight into Ensysce Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |